A panel from the Food and Drug Administration (FDA) with connections to the industry recommended easing regulations on six peptides. This decision was made despite objections from FDA scientists who cited insufficient data. Peptides are touted for benefits like faster healing, improved skin appearance, and extended lifespan, though evidence supporting their effectiveness and safety is limited.

During a meeting on Friday, the FDA advisory committee suggested that two more experimental peptides should be allowed for compounding. This meeting, which lasted two days, sparked debate over whether the FDA might be lowering its standards for preventing unverified drugs from reaching consumers.